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Philanthotoxin-433 (PhTX-433) is a known potent inhibitor of 
ionotropic glutamate receptors and analogues have been synthesized 
to identify more potent and selective antagonists. Here, we report on 
the synthesis of four PhTXs with a cyclopropane moiety introduced 
into their polyamine chain, and on their inhibition of an AMPA receptor 
subtype by using two-electrode voltage-clamp on Xenopus oocytes 
expressing the GluA1flop subunit. All analogues were more potent 
than PhTX-343 with trans-cyclopropyl-PhTX-343 being the most 
potent (~28-fold) and cis-cyclopropyl-PhTX-343 least potent (~4-fold). 
Both cis- and trans-cyclopropyl-PhTX-444 had intermediate potency 
(both ~12-fold). Molecular modelling indicates that a cyclopropane 
moiety confers a favourable steric constraint to the polyamine part but 
this is compromised by a cis conformation due to enhanced 
intramolecular folding. Elongated PhTX-444 analogues alleviate this 
to some extent but optimal positioning of the amines is not permitted. 
 
Introduction 
Philanthotoxin-433 (PhTX-433, 1; the numerals indicate the 
number of methylene groups spacing the nitrogens in the 
polyamine moiety; Figure 1) is a toxin found naturally in the 
venom of the solitary wasp, Philanthus triangulum.[1,2] PhTX-433 
and many of its synthetic analogues have been shown to have 
non-competitive inhibitory effects at both ionotropic glutamate 
receptors and nicotinic acetylcholine receptors.[3-6] In that respect 
PhTXs are attractive molecules to investigate further given that 
both of these receptor types are accepted as valid drug targets 
for a variety of neurodegenerative and other disorders of the 
central nervous system.[7] The modular butyryl-tyrosyl-
thermospermine composition of 1 has allowed for efficient 
generation of many synthetic analogues demonstrating the 
importance of all of these structure segments.[4,6,8-11] PhTXs 1, 2 
and an array of other analogues have been shown to produce 
powerful voltage-dependent inhibition of α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAR) currents 
suggesting a binding mode with the polyamine inserted deeply 
within the pore region of the ion channel.[3] This hypothesis is 
supported by the observation that AMPARs containing the GluA2 
subunit with arginine at the “Q/R” site in the selectivity filter of the 
pore exhibit drastically reduced inhibition by PhTX-343 and other 
polyamine-containing molecules.[12] 
In the last two decades advanced methodologies for solid-
phase synthesis (SPS) of polyamines have been developed,[13] 
however, no examples of SPS of cyclopropane-containing 
polyamine derivatives have been reported. The commonly used 
solution-phase method for obtaining polyamines displaying a 
cyclopropane moiety is alkylation of mesitylenesulfonamides with 
mesitylenesulfonates of cyclopropane diols, but this is not readily 
transferred into an SPS protocol due to the harsh conditions 
required for deprotonation of the sulfonamide and the risk of 
cross-linking the resin due to the bifunctional building block.[14] 
Cyclopropane-trans-1,2-dicarboxylic acid[15] may be readily 
obtained from the corresponding ethyl diester and the cis-
anhydride 3-oxabicyclo[3.1.0]hexane-2,4-dione was commercially 
available, and therefore, we chose an approach involving on-resin 
reduction of the diamide corresponding to the desired 4,4'-
dimethoxytrityl-protected polyamine.[16]  
In the present work we focus on incoporating 
unprecedented structural variations of the polyamine moiety 
present in both 1 and its well-studied close structural analogue, 
PhTX-343 (2), and examine how these influence the inhibitory 
effects of the resulting PhTX analogues on a specific subunit, 
GluA1flop, present in members of the AMPAR subdivision of the 
ionotropic glutamate receptor family. This subunit is characteristic 
of a calcium-permeable and polyamine-sensitive subtype of 
AMPARs, with the flop splice variant (a 38 amino acid region 
upstream of the fourth transmembrane region) being upregulated 
in place of the flip splice variant during early development to 
become dominating in adult CNS. Constraints were introduced in 
the central region of the polyamine moiety in an attempt to assess 
the importance of rigidity in this region. This was achieved by 
solid-phase synthesis incorporating cyclopropane moieties into 
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the polyamine chain to give trans- and cis-analogues with 3-4-3  
or 4-4-4 (i.e. PhTX-343- or PhTX-444-like) spacing between the 
nitrogens (3-6 = trans-343, trans-444, cis-343, cis-444, 
respectively; Figure 1). Analogues 2-6 were tested for inhibitory 
potency against homomeric rat GluA1flop AMPARs expressed in 
Xenopus oocytes by measurement of their reduction of currents 
evoked by stimulation with kainic acid (KA; 100 μM) by using a 
two-electrode voltage-clamp at a holding potential of –80 mV. 
Although KA is a weaker agonist of AMPARs it is often used 
instead of AMPA or L-Glu in these assays to avoid the problem of 
rapid receptor desensitization. 
 
Figure 1. Natural (1) and synthetic (2-6) target philanthotoxins (PhTXs). 
Results and Discussion 
Solid-phase synthesis of philanthotoxin analogues 
First, cyclopropane-trans-1,2-dicarboxylic acid diethyl ester (7) 
was converted into the corresponding pentafluorophenyl diester 8 
(Scheme 1) via alkaline hydrolysis and subsequent 
transesterification by using pentafluorophenyl trifluoroacetate–
pyridine (1:1) in DMF.[15,17] Building blocks 9a and 9b were 
obtained upon condensation of pentafluorophenyl diester 8 with 
one equivalent of the appropriate 2-(trimethylsilyl)ethoxycarbonyl 
(Teoc)-monoprotected diamine.[16b]   
In order to minimize cross-linking of the 2-chlorotrityl 
chloride resin, it was loaded with the appropriate Teoc-
monoprotected diamine (Scheme 2). A prolonged reaction time of 
two days enabled a cost-efficient use of these selectively 
protected diamines as only 10% excess was required. The 
resulting resin-bound diamines 10a/10b were then coupled with 
building blocks 9a/9b to give Teoc-protected diamide 
intermediates 11a/11b that were subjected to exchange of the N-
protecting group followed by borane reduction to yield the 4,4'-
dimethoxytrityl (Dmt)-protected polyamine intermediates 12a/12b. 
The thus formed secondary amino functionalities were Boc-
protected, and then the Dmt group on the terminal primary amine 
was removed under weakly acidic conditions to give selectively 
protected resin-bound polyamines 13a/13b. Successive acylation 
with the activated ester, Fmoc-Tyr(tBu)-OPfp, Fmoc deprotection, 
acylation with  pentafluorophenyl butanoate,[18] and cleavage from 
the linker afforded the crude trans-cyclopropane-containing target 
philanthotoxins that readily were pufied by reversed-phase 
preparative HPLC to give PhTXs 3 and 4 as the tris(TFA) salts.   
 
   
Scheme 1. Reagents and conditions: a) NaOH, H2O–EtOH; b) CF3COOPfp (2.5 
equiv), pyridine (2.5 equiv), DMF, 19 h; c) TeocNH(CH2)3NH2 or 
TeocNH(CH2)4NH2 (1 equiv), DIPEA (2 equiv), CH2Cl2, 19 h. DIPEA = 
diisopropylethylamine, Pfp = pentafluorophenyl, Teoc = 2-
(trimethylsilyl)ethoxycarbonyl.  
 
  
Scheme 2. Reagents and conditions: a) TeocNH(CH2)3NH2 or 
TeocNH(CH2)4NH2 (1.1 equiv), DIPEA (5 equiv), CH2Cl2, 2 days then CH2Cl2–
MeOH–DIPEA (85:15:5), 2 × 10 min; b) TBAF (3 equiv), DMF, 50 C, 1 h then 
room temperature for 3 h; c) Compound 9a or 9b (2 equiv), HODhBt (1 equiv), 
DIPEA (2 equiv), DMF, 16 h; d) TBAF (5 equiv), DMF, 55 C, 2 × 15 min; e) 
Dmt-Cl (6 equiv), DIPEA (6 equiv), CH2Cl2, 3.5 h then CH2Cl2–MeOH–DIPEA 
(85:15:5); f) 1M BH3.THF (20 equiv), THF, reflux for 16 h; g) Boc2O (10 equiv), 
DIPEA (10 equiv), CH2Cl2, 16 h; h) 0.1M chloroacetic acid, CH2Cl2, 4 × 30 min; 
i) Fmoc-Tyr(tBu)-OPfp (3 equiv), HODhBt (1 equiv), DIPEA (3 equiv), DMF, 2 × 
16 h; j) 20% piperidine–DMF, 2 × 10 min; k) C3H7COOPfp (3 equiv), HODhBt (1 
equiv), DIPEA (3 equiv), DMF, 16 h; l) TFA–CH2Cl2 (1:1), 2 h. TBAF: 
tetrabutylammmonium fluoride; Dmt-Cl: 4,4'-dimethoxytrityl chloride; HODhBt: 
3-hydroxy-1,2,3,-benzotriazin-4(3H)-one. 
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SPS of the corresponding cis-cyclopropane-containing PhTXs 
also started from resin-bound diamines 10a/10b, but in this case 
these were acylated with the cis-anhydride 3-oxabicyclo[3.1.0]-
hexane-2,4-dione to give intermediate resins 14a/14b. Elongation 
with the respective Teoc-monoprotected diamines under 
DIC/HOBt amide coupling conditions followed by removal of the 
Teoc group furnished the unprotected diamides 15a/15b. 
Introduction of the Dmt-protecting group and subsequent borane 
reduction of the amide fuctionalities gave rise to resins 16a/16b 
that upon Boc-protection and Dmt removal afforded primary 
amines 17a/17b that were acylated and cleaved from the resin as 
described for the trans-analogues to yield PhTXs 5 and 6 as the 
corresponding tris(TFA) salts upon purification. 
 
 
Scheme 3. Reagents and conditions: a) 3-oxabicyclo[3.1.0]hexane-2,4-dione (4 
equiv), DIPEA (2 equiv), DMF, 16 h; b) TeocNH(CH2)mNH2 (m = 3 or 4; 4 equiv), 
HOBt (4 equiv), DIC (4 equiv), DMF, 16 h; c) TBAF (5 equiv), DMF, 55 C, 2 × 
15 min; d) Dmt-Cl (6 equiv), DIPEA (6 equiv), CH2Cl2, 3.5 h then CH2Cl2–
MeOH–DIPEA (85:15:5); e) 1M BH3.THF (20 equiv), THF, reflux for 16 h; f) 
Boc2O (10 equiv), DIPEA (10 equiv), CH2Cl2, 16 h; g) 0.1M chloroacetic acid, 
CH2Cl2, 4 × 30 min; h) Fmoc-Tyr(tBu)-OPfp (3 equiv), HODhBt (1 equiv), DIPEA 
(3 equiv), DMF, 16 h; i) 20% piperidine–DMF, 2 × 10 min; j) C3H7COOPfp (3 
equiv), HODhBt (1 equiv), DIPEA (3 equiv), DMF, 16 h; k) TFA–CH2Cl2 (1:1), 2 
h.  
Receptor inhibition by philanthotoxins 
PhTX analogues 2-6 were all able to cause potent inhibition of 
currents evoked by exposure of oocytes to 100 μM KA (Figure 2) 
with their IC50 values given in Table 1. The present study is the 
first to report on PhTX-343 inhibition of homomeric rat GluA1flop 
channels while previous reports have focused on rat GluA1flip or 
AMPARs expressed from mRNA extracted from rat brain. We 
found that the IC50 for GluA1flop inhibition is similar to that for 
GluA1flip[12] but is about 10-fold higher than that observed for KA-
activated channels expressed from rat brain mRNA.[4,10] The 
subunit combination of the latter is not known, but presumably it 
contains other AMPAR subunits that may be more sensitive to 
PhTX 2. All of the cyclopropane-containing PhTX analogues (3-6) 
were significantly more potent inhibitors than 2, with the trans-
configured 3 being the most potent; nearly 30-fold more so than 
the corresponding straight-chain PhTX 2.  
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Figure 2. A) Current observed in response to exposure to 100 μM KA, and its 
inhibition following addition of 1 μM PhTX analogue 3 to an oocyte expressing 
GluA1flop at VH -80 mV. B) Concentration-inhibition curves for compounds 2-6 
in their inhibition of GluA1flop currents evoked by 100 μM KA. Points are 
mean % of control response ± SEM (n = 4-7 oocytes). IC50 values estimated 
from curve fits (Hill equation) are given in Table 1. 
 
Table 1. IC50 values for inhibition of 100 μM KA-evoked GluA1flop currents 
by PhTXs 2-6 and their relative potencies as compared to PhTX-343 (2). 
Compound IC50 ± SEM (μM) n (oocytes)[a] Relative potency[b] 
2 6.77 ± 1.41 6 1.0 
3 0.24 ± 0.04[c] 6 28.2 
4 0.54 ± 0.12[c] 7 12.5 
5 1.79 ± 0.50[d] 4 3.8 
6 0.57 ± 0.06[c] 6 11.9 
[a] Number of replicates each representing individual oocytes. [b] Ratio 
between IC50 values for PhTX 2 and each of the other PhTXs. [c] P < 0.0001 
(significance of difference by an extra sum of squares F-test compared to 2). 
[d] P < 0.001 (significance of difference by an extra sum of squares F-test 
compared to 2). 
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Modelling studies on philanthotoxins 
It is well known that the potency of a philanthotoxin analogue is 
influenced by changes in the length of the polyamine moiety as 
well as by the number and distribution of the positively charged 
amino groups as these factors determine the overall shape and 
electronic properties of the resulting molecule via intramolecular 
H-bonding.[3, 4, 19, 20]  
 
Figure 3. Structures of philanthotoxin analogues 2-6 visualizing the three 
general conformations that can be adopted: “head and tail” for 2 (A) and 3 (C), 
“semi-folded” for 4, 5 and 6 (D-F) and “folded” for 2 (B). G) A clearer view of H-
bonding (pink lines) between amide oxygens and amine hydrogens in 3 for an 
HT conformation and in 5 for a SF conformation. 
PhTX analogues can adopt three general low-energy 
structures, “head and tail” (HT; extended), “semi-folded” (SF) and 
“folded” (F) (as depicted in Figure 3), depending on whether H-
bonding involves the first, second, or third amino group, 
respectively. The HT structure is believed to be the most active at 
AMPARs due to previous observations showing that the mono-
cationic analogues are virtually inactive at AMPARs.[4,14] In terms 
of general shape mono-cationic analogues are “folded” because 
they do not possess a “tail” at all. Our modelling studies show that 
for all compounds the vast majority (99.8%) of low-energy 
conformations possessed at least one intramolecular H-bond. 
Ensembles of low-energy conformations obtained for the PhTX 
analogues studied contained all three types of structures (HT, SF 
and F) within 3 kcal mol-1 from the apparent energy minimum 
(0.5-1.0 kcal mol-1). To reveal the conformational preferences of 
the compounds we compared the relative numbers of 
conformations belonging to the different types within these 
ensembles. Compound 2 was found to be distributed as 85% HT 
(Figure 3A), 13% SF and 2% F (Figure 3B). This was unchanged 
for 3 so the additional hydrocarbon bulk, which in fact becomes 
part of the head group and relocating the tyrosyl group (Figure 
3C), appears to be responsible for the increased potency of 3. 
This is reminiscent of analogues where short hydrocarbon chains 
were introduced to the central section of the polyamine moiety 
resulting in more potent analogues at insect quisqualate sensitive 
ionotropic glutamate receptors.[9] The cis-analogue of 3 (i.e 
compound 5) was less potent as the cis arrangement caused the 
molecule to adopt a greater proportion of SF structure (44%) 
(Figure 3D) at the expense of HT (54%). The cause of this effect 
is that in the cis form both amino groups occur at the same side 
of the bulk and rigid cyclopropane ring. While the trans 
configuration dictates a rather large distance between amino 
groups (6.2 Å in the lowest-energy structure), the cis 
configuration results in a significantly smaller distance (4.6 Å). As 
a result, the probability that the second amino group is involved in 
intramolecular H-bonding (and thus the structure is semi-folded) 
is larger for the cis than the trans configuration (Figure 3G).  
PhTX analogues 4 and 6 showed intermediate potency 
between 3 and 5 since the additional carbon in the chain between 
the head group and the first amine functionality allowed for more 
flexibility and hence a higher proportion of SF structures (Figure 
3; E-F). The SF structures for these analogues are likely to be 
more active because of the longer chain between the second and 
terminal amine groups (giving it a more HT-like structure). 
Conclusion 
Introduction of a cyclopropane moiety between the first and 
second amino groups of PhTX-343 proved beneficial for AMPAR 
antagonism, but less so for the cis-analogue due to its greater 
tendency to become semi-folded as inferred by modeling studies. 
The positive (for trans-analogues) and negative (for cis-
analogues) effects of this structural alteration are to some extent 
obscured by the increased spacing of the amide and the first 
amine functionality as well as of the second and third amines, 
such that both PhTX-444 analogues display similar potency.  
Experimental Section 
General procedures. Unless otherwise stated, starting materials and 
solvents were purchased from commercial suppliers (H-Tyr(tBu)-OH 
from Novabiochem, reagents and solvents from Sigma-Aldrich, Fluka, 
or Lancaster) and used as received. CH2Cl2 was distilled from P2O5 
and stored over 4 Å molecular sieves. THF was distilled from 
Na/benzophenone immediately before use. 1H NMR and 13C NMR 
spectra were recorded at 400.14 MHz and 100.62 MHz, respectively, 
on a Bruker AMX 400 spectrometer, or at 300.06 MHz and 75.45 MHz, 
respectively, on a Varian Mercury Plus spectrometer, using CDCl3 or 
CD3OD as solvents and tetramethylsilane (TMS) as internal standard. 
Coupling constants (J values) are given in hertz (Hz), and 
multiplicities of 1H NMR signals are reported as follows: s, singlet; d, 
doublet; t, triplet; q, quartet; p, pentet, sx, sextet; m, mulitplet; br, 
broad. High-resolution mass spectrometry (HRMS) measurements 
were performed on a Bruker APEX Qe Fourier transform mass 
spectrometer equipped with a 9.4 tesla superconducting cryomagnet, 
and an external electrospray ion source (Apollo II source). The 
spectra were externally calibrated with an arginine cluster in positive 
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mode. The samples were dissolved in MeOH, introduced into the 
electrospray ion source using a syringe pump with a flow of 2 L/min. 
Solid-phase reactions were performed in Teflon filter vessels on a 
Scansys PLS 4 × 6 Organic Synthesizer equipped with a heating 
block. Preparative HPLC system consisted of an Agilent 1100 system 
with 2 preparative pump units, a UV detector, and a Phenomenex 
Luna C18(2) (5 m) column (25  2.12 cm). Linear elution gradients 
were composed by mixing solvent A (MeCN–H2O–TFA 5:95:0.1) and 
B (MeCN–H2O–TFA 95:5:0.1) at a flow rate of 20 mL/min. Analytical 
HPLC was performed on a Shimadzu system consisting of an SCL-
10A VP controller, an SIL-10AD VP autosampler, an LC-10AT VP 
pump, an SPD-M10A VP diode array detector, and a CTO-10AC VP 
column oven, using a Phenomenex Luna C18(2) (3) column (150  
4.6 mm). The HPLC system was controlled by Class VP 6 software; 
elution was performed with two different solvent systems (total flow of 
0.8 mL/minute). Solvent A = MeCN–H2O–TFA 10:90:0.1 and solvent 
B = MeCN–H2O–TFA 90:10:0.1; t = 0-5 min 0% B, t = 5-30 min 0-40% 
B, t = 30-35 min 40-100% B). The purities of target compounds 3-6 
were determined (from UV absorption integration at  = 215 nm) and 
were within the ranges 97-99%. 
Dipentafluorophenyl Cyclopropane-trans-1,2-dicarboxylate (8): 
Diethyl trans-1,2-cyclopropanedicarboxylate (7, 5.15 g, 27.7 mmol) 
was subjected to hydrolysis with NaOH (5.16 g, 4.66  27.7 mmol) in 
H2O–EtOH (2:1, 75 mL) for 4 h at room temperature. The reaction 
mixture was diluted with H2O (200 mL), and then washed with Et2O 
(100 mL), which was extracted back with H2O (50 mL). The combined 
aqueous phases were concentrated to dryness in vacuo. The residue 
was partially dissolved in EtOAc (100 mL), which then was filtered 
through a layer of Na2SO4. The filtrate was evaporated to give the 
crude diacid (2.98 g, 83%). The diacid (1.40 g, 10.8 mmol) was 
treated with CF3COOPfp (4.64 mL, 2.5  10.8 mmol) and pyridine 
(2.18 mL, 2.5  10.8 mmol) in dry DMF (15 mL) for 19 h under N2. 
The reaction mixture was diluted with EtOAc (250 mL), and then 
extracted successively with 0.1 M HCl (3  150 mL), saturated 
aqueous NaHCO3 (3  150 mL), and brine (150 mL). Upon drying 
(Na2SO4) the solvent was removed to give 8 (4.86 g, 98%). 
1H NMR 
(300 MHz, CDCl3):  1.81 (t, J = 7.5 Hz, 2H), 2.65 (t, J = 7.5 Hz, 
2H); 13C NMR (75 MHz, CDCl3):  = 17.6, 22.3 (2C), 124.5, 137.7 
(2C), 139.7, 141.0 (2C), 167.0. Anal. calcd for C17H4F10O4: C 44.18, H 
0.87, found: C 44.31, H 0.58. 
Protected Monoamides (9a/9b) from Dipentafluorophenyl 
Cyclopropane-trans-1,2-carboxylate: The diPfp ester (1.78 g, 3.85 
mmol) was dissolved in dry CH2Cl2 (25 mL), and then the appropriate 
Teoc-monoprotected diamine (3.85 mmol) and DIPEA (1.34 mL, 2  
3.85 mmol) in dry CH2Cl2 (10 mL), were added. After 19 h, the 
reaction mixture was diluted with EtOAc (150 mL), and then washed 
with 0.1 M HCl–brine (3:1, 3 × 100 mL), H2O (100 ml), satd NaHCO3–
brine (3:1, 3 × 100 mL), and brine (75 mL). The organic layer was 
dried (Na2SO4) and concd. The residue was dissolved in CH2Cl2 (15 
mL) and loaded onto a VLC column (5.5 × 6 cm), which was eluted 
with hexane and then hexane–Me2CO 20:1 to 4:1. This afforded 9a 
(1.24 g, 65%) or 9b (1.10 g, 56%). 9a: 1H NMR (300 MHz, CDCl3):  
0.03 (s, 9H), 0.97 (br t, J = 8.5 Hz, 2H), 1.52 (ddd, J = 9.2, 5.5, 4.1 Hz, 
1H), 1.61-1.71 (br m, 3H), 2.20 (ddd, J = 9.2, 6.0, 3.9 Hz, 1H), 2.48 
(ddd, J = 9.1, 5.5, 3.9 Hz, 1H), 3.35 (m, 2H), 3.24 (m, 2H), 4.14 (br t, J 
= 8.5 Hz, 2H), 5.05 (br s, 1H), 6.84 (br s, 1H) ppm; 13C NMR (75 MHz, 
CDCl3):  –1.4, 16.2, 17.8, 20.3, 25.6, 30.1, 36.3, 37.5, 62.3, 157.5, 
168.7, 169.1 ppm. HRMS m/z [M+Na]+ calcd for C20H25F5N2NaO5Si: 
519.13451, found 519.13431. 9b: 1H NMR (300 MHz, CDCl3):  = 
0.02 (s, 9H), 0.96 (br t, J = 8.5 Hz, 2H), 1.51 (ddd, J = 9.0, 5.5, 3.9 Hz, 
1H), 1.56 (m, 4H), 1.77 (ddd, J = 9.0, 6.1, 3.9 Hz, 1H), 2.16 (ddd, J = 
9.0, 6.1, 3.9 Hz, 1H), 2.47 (ddd, J = 9.0, 5.5, 3.9 Hz, 1H), 3.32 (m, 2H), 
3.29 (m, 2H), 4.13 (br t, J = 8.5 Hz, 2H), 4.79 (br s, 1H), 6.43 (br s, 
1H) ppm; 13C NMR (75 MHz, CDCl3):  –1.4, 16.1, 17.9, 20.3, 25.5, 
26.5, 27.8, 39.7, 40.4, 63.1, 156.9, 168.7, 168.9 ppm. HRMS m/z 
[M+Na]+ calcd for C21H27F5N2NaO5Si: 533.15016, found 533.14995. 
Preparation of resin-bound diamines 10a/10b: N1-[2-
Trimethylsilyl)ethoxycarbonyl)]-1,3-propanediamine was prepared (in 
74% yield) as earlier reported for N1-[2-trimethylsilyl)ethoxycarbonyl)]-
1,4-butanediamine.[16b] 1H NMR (300 MHz, CDCl3):  = 0.02 (s, 9H), 
0.96 (t, J =  8.5 Hz, 2H), 1.67 (p, J =  6.6 Hz, 2H), 2.82 (t, J =  6.6 Hz, 
2H), 3.26 (m, 2H), 4.12 (br t, J =  8.5 Hz, 2H) ppm; 13C NMR (75 MHz, 
CDCl3):  = –1.2, 17.9, 38.8, 39.4, 62.9, 157.0 ppm. Trityl chloride 
resin (1.89 g, ~2.2 mmol/g) prewashed with 10% DIPEA–CH2Cl2 was 
added to a gently stirred solution of Teoc-monoprotected diamine (1.1 
× 4.16 mmol) and DIPEA (3.6 mL, 5 × 4.16 mmol) in dry CH2Cl2 (20 
mL). After 2 days, the resin was transferred to a 20 mL syringe, and 
then washed with CH2Cl2 (2 ×15 mL) and subsequently end-capped 
with CH2Cl2–MeOH–DIPEA (80:15:5, 15 mL, 2 × 10 min). The resin 
was then washed with CH2Cl2, MeOH, dry CH2Cl2 (each 3×), dried 
overnight (to give 2.52 g and 2.57 g, respectively of resin-bound 
Teoc-protected 1,3-propanediamine and 1,4-butanediamine, 
repectively). Then the Teoc groups were removed by treatment with 
TBAF (3 equiv) in dry DMF (45 mL; in a round-bottomed flask) at 50 
C for 1 h and then at room temperature for 3 h. The resins were then 
washed with CH2Cl2, MeOH, dry CH2Cl2 (each 3×), dried overnight (to 
give ~2.0 g, 10a/10b). The loadings were determined to be ~1.8 
mmol/g based on the mass gain and coupling with Fmoc-Gly-OH. 
SPS of Protected trans-Cyclopropane PhTX-Analogues: Resin-
bound diamines (10a/10b, 0.44 mmol) were swelled in dry DMF for 30 
min. The solvent was removed by suction, and the resin was treated 
with a cyclopropane building block (9a or 9b, 2 equiv), HODhBt (1 
equiv) and DIPEA (2 equiv) in dry DMF (10 mL/mmol resin). The 
mixture was shaken for 16 h at room temperature. The resin was 
drained and then washed with DMF, MeOH, CH2Cl2 and DMF (3 × 12 
mL/mmol resin with each solvent). The Teoc group was removed by 
treatment with TBAF (5 equiv) in DMF (7.5 mL/mmol resin) at 55 C 
for 15 min. Upon draining and wash with DMF, this deprotection step 
was repeated. The resin was drained and then washed with DMF, 
MeOH, and CH2Cl2 (3 ×). Dmt-Cl (6 equiv) in dry CH2Cl2 (9 mL/mmol 
resin) and DIPEA (6 equiv) were added to the resin. After 3.5 h, the 
resin was drained and washed with CH2Cl2, CH2Cl2–MeOH–DIPEA 
(80:15:5), DMF, CH2Cl2, and THF (each 3 ×). The resin was 
transferred to a 25 mL flask with a minimum of THF, and then 1M 
BH3∙THF in THF (20 equiv) was added. The flask was heated to reflux 
under N2 in an oil bath (70 C) for 16 h. The resin was transferred 
back to a teflon reactor using THF. Upon draining, the resin was 
washed with MeOH (3 ×). Then the resin was treated with piperidine 
(9 mL/mmol resin) at 60 C for 1.5 h. After washing with MeOH (12 
mL/mmol), this decomplexation procedure was repeated twice. The 
resin was treated with Boc2O (10 equiv) and DIPEA (10 equiv) in dry 
CH2Cl2 (6 mL/mmol resin) for 16 h followed by draining and wash with 
DMF, MeOH, DMF, and CH2Cl2 (each 3 ×). Dmt deprotection with 
0.1M ClAcOH in CH2Cl2 (14 mL/mmol resin) for 30 min followed by 
wash with CH2Cl2 was repeated three times. The resin was drained 
and washed with DMF, MeOH, CH2Cl2, and dry DMF (each 3 ×). The 
resulting resin was coupled with Fmoc-Tyr(tBu)-OPfp (3 equiv), 
HODhBt (1 equiv), and DIPEA (3 equiv) in dry DMF (7 mL/mmol 
resin) for 16 h. Upon draining, the resin was washed with DMF, 
MeOH, CH2Cl2, and dry DMF (each 3 ×). Coupling with Fmoc-
Tyr(tBu)-OPfp was repeated (due to a positive Kaiser test) using 
DMF–CH2Cl2 (3:1) as solvent. Fmoc deprotection with 20% 
piperidine–DMF (11 mL/mmol resin) for 10 min was repeated after a 
DMF wash. Upon draining, the resin was washed with DMF, MeOH, 
CH2Cl2, and dry DMF (each 3 ×). The resulting resin was treated with 
pentafluorophenyl butanoate (3 equiv), HODhBt (1 equiv), and DIPEA 
(3 equiv) in dry DMF (8 mL/mmol resin) for 16 h. Upon draining, the 
resin was washed with DMF, MeOH, and CH2Cl2 (each 3 ×). 
Cleavage of the product from the resin was performed with TFA–
CH2Cl2 (1:1, 9 mL/mmol resin) for 2 h. The filtrate was collected by 
suction, and the resin eluted further with CH2Cl2 and MeOH (each 2 × 
9 mL/mmol resin). The combined filtrates were concentrated, and the 
residue purified by preparative HPLC (>95% purity): 3 (46 mg) and 4 
(115 mg). 3: 1H NMR (300 MHz, methanol-d4):  0.85 (br t, J = 6.6 
Hz, 2H), 0.87 (t, J = 7.4 Hz, 3H), 1.22 (m, 2H), 1.56 (sx, J = 7.4 Hz, 
2H), 1.81 (br p, J = 6.5 Hz, 2H), 2.10 (m, 2H), 2.18 (t, J = 7.4 Hz, 2H), 
2.82–3.30 (br m, 14H), 4.49*/4.50* (t, J = 7.7 Hz, 1H), 6.71 (d, J = 8.3 
Hz, 2H), 7.06 (d,  J = 8.3 Hz, 2H); 13C NMR (75 MHz, methanol-d4):  
= 10.8, 14.0, 15.5*,**, 15.6*, 20.3, 25.4, 27.5*/27.4*, 36.7, 37.8, 38.0, 
 6 
38.6, 45.6, 46.0*/45.9*, 52.1, 52.2, 57.1, 116.2, 117.6, 128.7, 131.1, 
157.2, 162.1, 175.1*/175.0*, 176.0; *signals with half intensity (splitting 
due to presence of diastereomers); **two distinct close signals. HRMS 
m/z [M+H]+ calcd for C24H42N5O3: 448.32822, found 448.32830. 4: 
1H 
NMR (300 MHz, methanol-d4):  = 0.84 (t, J = 7.4 Hz, 3H), 0.84 (obsc., 
2H), 1.22 (m, 2H), 1.53 (sx, J = 7.4 Hz, 2H), 1.42–1.66 (br m, 4H), 
1.67–1.85 (br m, 4H), 2.16 (t, J = 7.4 Hz, 2H), 2.79 (dd, J = 13.7 and 
8.5 Hz, 1H), 2.87–3.15 (br m, 13H), 4.52 (dd, J = 8.5 and 6.9 Hz, 1H), 
6.69 (d, J = 8.5 Hz, 2H), 7.04 (d, J = 8.5 Hz, 2H) ppm; 13C NMR (75 
MHz, methanol-d4):  = 11.0, 14.0, 15.4 (2C), 20.3, 24.2, 24.3, 25.6, 
27.3, 38.2, 38.7, 39.3, 40.0, 47.9, 48.2, 51.8, 52.0, 56.8, 116.1, 117.7, 
128.9, 131.1, 157.1, 162.4, 173.9, 175.8. HRMS m/z [M+H]+ calcd for 
C26H46N5O3: 476.35952, found 476.35956. 
SPS of Protected cis-Cyclopropane PhTX-Analogues: Resin-
bound diamines (10a/10b, 0.55 mmol) were swelled in dry DMF for 30 
min. The solvent was removed by suction, and a solution of 3-
oxabiclo[3.1.0]hexane-2,4-dione (4 equiv) and DIPEA (2 equiv) in dry 
DMF (7 mL/mmol resin) was added to the resin. After 16 h, the resin 
was drained and washed with DMF, MeOH, DMF, and dry CH2Cl2 
(each 3 × 12 mL/mmol resin). Then the resin was treated with Teoc-
monoprotected diamine (4 equiv), HOBt (4 equiv), and DIC (3 equiv) 
in dry DMF (8 mL/mmol resin) for 16 h. The resin was drained and 
washed with DMF, MeOH, DMF, and dry CH2Cl2 (each 3 ×). 
Successive Teoc deprotection, introduction of Dmt protecting groups, 
borane reduction/decomplexation, and Boc protection were performed 
as described above for trans-analogues. Upon draining and wash with 
DMF, MeOH, DMF, and CH2Cl2 (each 3 ×), Dmt groups were 
removed with 0.1M ClAcOH in CH2Cl2 (11 mL/mmol resin, 4 × 30 min). 
The resin was drained and washed with DMF, MeOH, CH2Cl2, and dry 
DMF (each 3 ×). The resulting resin was elongated with the Tyr 
residue, and subsequently terminated by introduction of the N-butyryl 
group as described above (using single couplings for 16 h). Cleavage 
of the product from the resin was performed with TFA–CH2Cl2 (1:1, 7 
mL/mmol resin) for 2 h. The crude products were purified by 
preparative HPLC (>95% purity): 5 (220 mg) and 6 (64 mg). 5: 1H 
NMR (300 MHz, methanol-d4):  = 0.56
*/0.58* (q, J = 5.8 Hz, 1H), 
0.85*/0.86* (t, J = 7.5 Hz, 3H), 1.11 (m, 1H), 1.39 (m, 2H), 1.54*/1.56* 
(sx, J = 7.5 Hz, 2H), 1.82 (p, J = 6.6 Hz, 2H), 2.15–2.22 (br m, 4H), 
2.79–3.30 (br m, 14H), 4.39*/4.40* (t, J = 7.7 Hz, 1H), 6.72 (d, J = 8.4 
Hz, 2H), 7.06*/7.07* (d, J = 8.4 Hz, 2H) ppm; 13C NMR (75 MHz, 
methanol-d4):  = 10.2
*/10.5*, 13.8*,**/13.9*, 14.0**, 20.3, 25.4, 27.4, 
36.7*/36.8*, 37.8, 38.0*,**, 38.6*,**, 45.7*,**/45.8*,**, 46.0*,**, 48.4 (2C), 
57.0*/57.2*, 116.1*/116.2*, 118.0, 128.8, 131.1*/131.2*, 157.2*,**, 162.9, 
174.9*/175.1*, 176.0*,** ppm; *signals with half intensity (splitting due to 
presence of diastereomers); **two distinct close signals. HRMS m/z 
[M+H]+ calcd for C24H42N5O3: 448.32822, found 448.32802. 6: 
1H 
NMR (300 MHz, methanol-d4):  = 0.60 (q, J = 5.5 Hz, 1H), 0.85 (t, J = 
7.4 Hz, 3H), 1.12 (m, 1H), 1.39 (m, 2H), 1.45–1.68 (br m, 4H), 1.54 
(sx, J = 7.4 Hz, 2H), 1.77 (m, 4H), 2.16 (t, J = 7.4 Hz, 2H), 2.80 (dd, J 
= 13.7 and 8.5 Hz, 1H), 2.89–3.38 (br m, 13H),  4.42 (dd, J = 8.5 and 
6.9 Hz, 1H), 6.70 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 8.5 Hz, 2H) ppm; 
13C NMR (75 MHz, methanol-d4):  = 10.6, 13.8
**, 14.0, 20.3, 24.2, 
24.3, 25.6, 27.3, 38.2, 38.7, 39.3, 40.0, 48.0, 48.2, 48.3 (2C), 56.9, 
116.1, 118.0, 128.9, 131.1, 157.1, 162.7, 173.9, 175.9 ppm; **two 
distinct close signals. HRMS m/z [M+H]+ calcd for C26H46N5O3: 
476.35952, found 476.35936.  
AMPAR Inhibition Assay. A two-electrode voltage-clamp (TEVC) 
was used to record responses to 100 M KA of Xenopus laevis 
oocytes expressing AMPARs containing GluA1flop subunits. X. laevis 
oocytes were injected with cRNA encoding GluA1flop and incubated 
at 18 C for at least three days. Single oocytes were transferred to a 
perfusion bath and continuously washed with saline containing 96 mM 
NaCl, 2 mM  KCl, 2 mM CaCl2, 1 mM MgCl2 and 5 mM HEPES (pH 
adjusted 7.5 with NaOH). Microelectrodes were pulled from 
borosilicate glass capillaries (GC150TF-10, Harvard Apparatus) using 
a Sutter P-97 programmable puller and had resistances of ~0.5 MΩ 
when filled with 3.0 M KCl. The oocytes were voltage clamped at –80 
mV using an Axoclamp 2B (Axon Instruments) and output currents 
were transferred to a PC via a NI PCI-6221 A-D interface (National 
Instruments, UK) and WinEDR software (Dr John Dempster, 
University of Strathclyde, UK). Responses of AMPAR were elicited by 
perfusion of 100 M KA until a stable control current was obtained 
(60-90 s) then 2-6 were co-applied until a new plateau current was 
obtained (60-90 s). This was repeated for 2-6 concentrations in the 
range 10-9 – 10-5 M (+ 10-4 M for 2). Percent of control response was 
plotted against concentration of PhTX analogue and fit with a Hill 
equation to estimate the IC50. Analysis was performed using 
GraphPad Prism 6.  
Molecular Modelling. Calculations were performed by using ZMM 
(ZMM Software, Inc., Flamborough, Ontario, Canada). The non-
bonded interactions were calculated by using the AMBER force 
field[21] with a cut-off distance of 8 Å. The hydration energy was 
calculated by using the implicit solvent method.[22] Electrostatic 
interactions were calculated by using the distance-dependent 
dielectric function ε = 4r where (r) is the atom-atom distance. No 
specific energy terms were used for cation-π interactions, which were 
accounted for with partial negative charges at the aromatic 
carbons.[23] Bond lengths and valent angles were assigned standard 
values. Atomic charges at ligands were calculated by using the AM1 
method in the MOPAC program. For each ligand, 100 starting 
conformations were generated by randomizing torsion angle values. 
The Monte Carlo minimization (MCM) method[24] was used to optimize 
the structures. MCM of each model was performed until 600 
consecutive energy minimizations did not decrease the energy of the 
apparent global minimum. For statistical analysis, the 1000 lowest 
energy conformations were selected. 
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